Tesaglitazar: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:Tesaglitazar}} | |||
== | == Tesaglitazar == | ||
[[File:Tesaglitazar_free_acid.png|thumb|right|Chemical structure of Tesaglitazar]] | |||
'''Tesaglitazar''' is a [[pharmaceutical drug]] that was developed as a dual [[peroxisome proliferator-activated receptor]] (PPAR) [[agonist]]. It was designed to target both the [[PPAR-alpha]] and [[PPAR-gamma]] receptors, which are involved in the regulation of [[lipid metabolism]] and [[glucose homeostasis]]. | |||
== Mechanism of Action == | == Mechanism of Action == | ||
Tesaglitazar | Tesaglitazar functions by activating the PPAR-alpha and PPAR-gamma receptors. These receptors are [[nuclear receptors]] that regulate the expression of genes involved in [[fatty acid oxidation]], [[lipid metabolism]], and [[insulin sensitivity]]. By activating these receptors, Tesaglitazar aims to improve [[insulin resistance]] and reduce [[triglyceride]] levels, which are beneficial effects for patients with [[type 2 diabetes mellitus]] and [[dyslipidemia]]. | ||
== Clinical Trials == | == Development and Clinical Trials == | ||
Tesaglitazar was developed by [[AstraZeneca]] and underwent several [[clinical trials]] to evaluate its efficacy and safety. The drug showed promise in improving [[glycemic control]] and lipid profiles in patients with type 2 diabetes. However, during the clinical trials, concerns arose regarding potential adverse effects, including [[cardiovascular risk]] and [[renal impairment]]. | |||
== | == Adverse Effects == | ||
The clinical trials of Tesaglitazar revealed several adverse effects that raised concerns about its safety profile. These included increased risk of [[edema]], [[weight gain]], and potential [[cardiovascular events]]. Additionally, there were indications of [[renal function]] impairment, which led to further scrutiny of its long-term safety. | |||
== Discontinuation == | |||
Due to the safety concerns identified during the clinical trials, the development of Tesaglitazar was eventually discontinued. The decision was made to halt further development and marketing of the drug, as the risks were deemed to outweigh the potential benefits. | |||
== Related Pages == | |||
* [[Peroxisome proliferator-activated receptor]] | |||
* [[Type 2 diabetes mellitus]] | |||
* [[Lipid metabolism]] | |||
* [[Insulin resistance]] | |||
* [[AstraZeneca]] | * [[AstraZeneca]] | ||
[[Category:Pharmaceutical drugs]] | [[Category:Pharmaceutical drugs]] | ||
[[Category: | [[Category:PPAR agonists]] | ||
[[Category: | [[Category:Discontinued drugs]] | ||
Latest revision as of 11:11, 15 February 2025
Tesaglitazar[edit]
Tesaglitazar is a pharmaceutical drug that was developed as a dual peroxisome proliferator-activated receptor (PPAR) agonist. It was designed to target both the PPAR-alpha and PPAR-gamma receptors, which are involved in the regulation of lipid metabolism and glucose homeostasis.
Mechanism of Action[edit]
Tesaglitazar functions by activating the PPAR-alpha and PPAR-gamma receptors. These receptors are nuclear receptors that regulate the expression of genes involved in fatty acid oxidation, lipid metabolism, and insulin sensitivity. By activating these receptors, Tesaglitazar aims to improve insulin resistance and reduce triglyceride levels, which are beneficial effects for patients with type 2 diabetes mellitus and dyslipidemia.
Development and Clinical Trials[edit]
Tesaglitazar was developed by AstraZeneca and underwent several clinical trials to evaluate its efficacy and safety. The drug showed promise in improving glycemic control and lipid profiles in patients with type 2 diabetes. However, during the clinical trials, concerns arose regarding potential adverse effects, including cardiovascular risk and renal impairment.
Adverse Effects[edit]
The clinical trials of Tesaglitazar revealed several adverse effects that raised concerns about its safety profile. These included increased risk of edema, weight gain, and potential cardiovascular events. Additionally, there were indications of renal function impairment, which led to further scrutiny of its long-term safety.
Discontinuation[edit]
Due to the safety concerns identified during the clinical trials, the development of Tesaglitazar was eventually discontinued. The decision was made to halt further development and marketing of the drug, as the risks were deemed to outweigh the potential benefits.
